Showing results (191-200 of 213) with videos related to
Sort By:
Pageof 22
Biomacromolecules|August 2, 2016
Bioinspired Functionalized Melanin Nanovariants with a Range of Properties Provide Effective Color Matched Photoprotection in SkinManika Vij, Ritika Grover, Vishvabandhu Gotherwal, et al.Organic & Biomolecular Chemistry|October 8, 2016
Biphenyl urea derivatives as selective CYP1B1 inhibitorsMohd Usman Mohd Siddique, Glen J P McCann, Vinay Sonawane, et al.The Journal of Antimicrobial Chemotherapy|July 5, 2021
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacyIsabel Barceló, Gabriel Cabot, Snehal Palwe, et al.The Lancet Regional Health. Southeast Asia|October 6, 2025
Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trialHimanshu Pophale, Monica Gupta, Lily Llorens, et al.European Journal of Medicinal Chemistry|August 2, 2016
6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitorsRammohan R Yadav, Santosh K Guru, Prashant Joshi, et al.Journal of Medicinal Chemistry|August 12, 2014
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activityShreyans K Jain, Surjeet Singh, Anamika Khajuria, et al.Bioorganic & Medicinal Chemistry Letters|November 16, 2017
(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agentNeill J Horley, Kenneth J M Beresford, Supriya Kaduskar, et al.Plos Medicine|May 4, 2010
The effect of rural-to-urban migration on obesity and diabetes in India: a cross-sectional studyShah Ebrahim, Sanjay Kinra, Liza Bowen, et al.The Indian Journal of Medical Research|June 6, 2012
Impact of comprehensive cardiovascular risk reduction programme on risk factor clustering associated with elevated blood pressure in an Indian industrial populationPanniyammakal Jeemon, Dorairaj Prabhakaran, Shifalika Goenka, et al.Lancet (London, England)|April 29, 2008
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry dataDenis Xavier, Prem Pais, P J Devereaux, et al.Pageof 22